Interstitial lung disease.

People’s Medical Publishing House, Shelton, CTTravis W.D. Costabel U. Hansell D.M. et al.

An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.

Am J Respir Crit Care Med. 188: 733-748

American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias.

Am J Respir Crit Care Med. 165: 277-304Coultas D.B. Zumwalt R.E. Black W.C. et al.

The epidemiology of interstitial lung diseases.

Am J Respir Crit Care Med. 150: 967-972Thomeer M.J. Costabe U. Rizzato G. et al.

Comparison of registries of interstitial lung diseases in three European countries.

Eur Respir J Suppl. 32: 114s-118sSkeoch S. Weatherley N. Swift A.J. et al.

Drug-Induced Interstitial Lung Disease: A Systematic Review.

J Clin Med. 7https://doi.org/10.3390/jcm7100356

The Drug-induced respiratory disease website.

Pneumotox. () ()

Iatrogenic pulmonary lesions.

Semin Diagn Pathol. 35: 260-271Camus P. Foucher P. Bonniaud P. et al.

Drug-induced infiltrative lung disease.

Eur Respir J. 18: 93s

Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches.

Respir Res. 13: 39Zhai X. Zhang J. Tian Y. et al.

The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients.

Cancer Biol Med. 17: 599-611

Pathologic mechanisms of drug-induced lung disorders.

J Thorac Imaging. 6: 1-7Erasmus J.J. McAdams H.P. Rossi S.E.

High-resolution CT of drug-induced lung disease.

Radiol Clin North Am. 40: 61-72

Type IV Hypersensitivity Reaction.

in: StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL) () ()Guillon J.M. Joly P. Autran B. et al.

Minocycline-induced cell-mediated hypersensitivity pneumonitis.

Ann Intern Med. 117: 476-481Ramos-Casals M. Brahmer J.R. Callahan M.K. et al.

Immune-related adverse events of checkpoint inhibitors.

Nat Rev Dis Primers. 6: 38Spagnolo P. Bonniaud P. Rossi G. et al.

Drug-induced interstitial lung disease.

Eur Respir J. 2102776https://doi.org/10.1183/13993003.02776-2021Hradska K. Hajek R. Jelinek T.

Toxicity of Immune-Checkpoint Inhibitors in Hematological Malignancies. Review.

Front Pharmacol. https://doi.org/10.3389/fphar.2021.733890Stone J.R. Kanneganti R. Abbasi M. et al.

Monitoring for Chemotherapy-Related Cardiotoxicity in the Form of Left Ventricular Systolic Dysfunction: A Review of Current Recommendations.

JCO Oncol Pract. 17: 228-236

Cardiotox: the drug-induced cardiovascular disease app. Version 1.0. Cactus Mobile. Updated August 23, 2022.

Naranjo C.A. Busto U. Sellers E.M. et al.

A method for estimating the probability of adverse drug reactions.

Clin Pharmacol Ther. 30: 239-245Müller N.L. White D.A. Jiang H. et al.

Diagnosis and management of drug-associated interstitial lung disease.

Br J Cancer. 91: S24-S30Common terminology criteria for adverse events (CTCAE), version 5.0. U.S. Department of Health and Human Services. () ()Inomata S. Takahashi H. Nagata M. et al.

Acute lung injury as an adverse event of gefitinib.

Anti Cancer Drugs. 15: 461-467Ohnishi H. Yokoyama A. Yasuhara Y. et al.

Circulating KL-6 levels in patients with drug induced pneumonitis.

Thorax. 58: 872-875Wang K. Ju Q. Cao J. et al.

Impact of serum SP-A and SP-D levels on comparison and prognosis of idiopathic pulmonary fibrosis: A systematic review and meta-analysis.

Med (Baltimore). 96: e7083Tong M. Xiong Y. Zhu C. et al.

Serum surfactant protein D in COVID-19 is elevated and correlated with disease severity.

BMC Infect Dis. 21: 737Meyer K.C. Raghu G. Baughman R.P. et al.

An Official American Thoracic Society Clinical Practice Guideline: The Clinical Utility of Bronchoalveolar Lavage Cellular Analysis in Interstitial Lung Disease.

Am J Respir Crit Care Med. 185: 1004-1014Costabel U. Uzaslan E. Guzman J.

Bronchoalveolar lavage in drug-induced lung disease.

Clin Chest Med. 25: 25-35Costabel U. Guzman J. Bonella F. et al.

Bronchoalveolar lavage in other interstitial lung diseases.

Semin Respir Crit Care Med. 28: 514-524Miyashita N. Nakajima M. Kuroki M. et al.

[Sulbactam/ampicillin-induced pneumonitis].

Nihon Kokyuki Gakkai Zasshi. 36: 684-689Brutinel W.M. Martin W.J.

Chronic Nitrofurantoin Reaction Associated with T-Lymphocyte Alveolitis.

Chest. 89: 150-152Morelon E. Stern M. Israël-Biet D. et al.

Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients.

Transplantation. 72: 787-790Schnabel A. Richter C. Bauerfeind S. et al.

Bronchoalveolar lavage cell profile in methotrexate induced pneumonitis.

Thorax. 52: 377-379Cleverley J.R. Screaton N.J. Hiorns M.P. et al.

Drug-induced lung disease: high-resolution CT and histological findings.

Clin Radiol. 57: 292-299

Pathologic characteristics of drug-induced lung disease.

Clin Chest Med. 25: 37-45Camus P. Fanton A. Bonniaud P. et al.

Interstitial Lung Disease Induced by Drugs and Radiation.

Respiration. 71: 301-326Sitbon O. Bidel N. Dussopt C. et al.

Minocycline Pneumonitis and Eosinophilia: A Report on Eight Patients.

Arch Intern Med. 154: 1633-1640

Amiodarone pulmonary toxicity.

Can Respir J. 16: 43-48Johkoh T. Lee K.S. Nishino M. et al.

Chest CT Diagnosis and Clinical Management of Drug-related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper from the Fleischner Society.

Radiol. 298: 550-566Myers J.L. Limper A.H. Swensen S.J.

Drug-induced lung disease: a pragmatic classification incorporating HRCT appearances.

Semin Respir Crit Care Med. 24: 445-454

Drug-induced lung diseases: most common reaction patterns and corresponding high-resolution CT manifestations.

Semin Ultrasound CT MR. 27: 111-116

Chemotherapy-induced lung disease.

Clin Chest Med. 25: 53-64Dimopoulou I. Bamias A. Lyberopoulos P. et al.

Pulmonary toxicity from novel antineoplastic agents.

Ann Oncol. 17: 372-379Fujimoto D. Kato R. Morimoto T. et al.

Characteristics and Prognostic Impact of Pneumonitis during Systemic Anti-Cancer Therapy in Patients with Advanced Non-Small-Cell Lung Cancer.

PLoS One. 11: e0168465Li F. Liu H. Wu H. et al.

Risk factors for radiation pneumonitis in lung cancer patients with subclinical interstitial lung disease after thoracic radiation therapy.

Radiat Oncol. 16: 70

Pulmonary Complications of Novel Antineoplastic Agents for Solid Tumors.

Chest. 133: 528-538O'Driscoll B.R.M.D.M. Hasleton P.S.M.D.F. Taylor P.M.M.F. et al.

Active Lung Fibrosis Up to 17 Years after Chemotherapy with Carmustine (BCNU) in Childhood.

N Engl J Med. 323: 378-382Beynat-Mouterde C. Beltramo G. Lezmi G. et al.

Pleuroparenchymal fibroelastosis as a late complication of chemotherapy agents.

Eur Respir J. 44: 523O'Sullivan J.M. Huddart R.A. Norman A.R. et al.

Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours.

Ann Oncol. 14: 91-96Delanoy N. Pécuchet N. Fabre E. et al.

Bleomycin-Induced Pneumonitis in the Treatment of Ovarian Sex Cord–Stromal Tumors: A Systematic Review and Meta-analysis.

Int J Gynecol Cancer. 25: 1593Ngeow J. Tan I.B. Kanesvaran R. et al.

Prognostic impact of bleomycin-induced pneumonitis on the outcome of Hodgkin’s lymphoma.

Ann Hematol. 90: 67-72Stamatoullas A. Brice P. Bouabdallah R. et al.

Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: frequent pulmonary events suggest limiting the use of bleomycin in the elderly.

Br J Haematol. 170: 179-184Evens A.M. Helenowski I. Ramsdale E. et al.

A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era.

Blood. 119: 692-695Broaddus V.C. Ernst J.D. King T.E. et al.

Murray & Nadel's Textbook of Respiratory Medicine E-Book.

Elsevier Health Sciences. Ruscitti F. Ravanetti F. Bertani V. et al.

Quantification of Lung Fibrosis in IPF-Like Mouse Model and Pharmacological Response to Treatment by Micro-Computed Tomography. Original Research.

Front Pharmacol. https://doi.org/10.3389/fphar.2020.01117Oliner H. Schwartz R. Rubio F. et al.

Interstitial pulmonary fibrosis following busulfan therapy.

Am J Med. 31: 134-139About I. Lauque D. Levenes H. et al.

[Alveolar opacities and busulfan pneumonia].

Rev Mal Respir. 10 (): 39-41Kedia R.K. Sullivan A. Stephens M. et al.

A breathless female.

Eur Respir J. 13: 207-209

Busulphan lung.

Thorax. 23: 187-193Malik S.W. Myers J.L. DeRemee R.A. et al.

Lung toxicity associated with cyclophosphamide use. Two distinct patterns.

Am J Respir Crit Care Med. 154: 1851-1856Anoop T.M. Joseph R. Unnikrishnan P. et al.

Taxane-induced acute interstitial pneumonitis in patients with breast cancer and outcome of taxane rechallenge.

Lung India. 39: 158-168Bielopolski D. Evron E. Moreh-Rahav O. et al.

Paclitaxel-induced pneumonitis in patients with breast cancer: case series and review of the literature.

J Chemother. 29: 113-117Ostoros G. Pretz A. Fillinger J. et al.

Fatal pulmonary fibrosis induced by paclitaxel: a case report and review of the literature.

Int J Gynecol Cancer. 16: 391-393Ardolino L. Lau B. Wilson I. et al.

Case Report: Paclitaxel-Induced Pneumonitis in Early Breast Cancer: A Single Institution Experience and Review.

Front Oncol. 11: 701424https://doi.org/10.3389/fonc.2021.701424Fujimaki T. Kato K. Fukuda S. et al.

Acute interstitial pneumonitis after implantation of paclitaxel-eluting stents: a report of two fatal cases.

Int J Cardiol. 148: e21-e24Bukamur H. Alkrekshi A. Katz H. et al.

Immune Checkpoint Inhibitor-Related Pulmonary Toxicity: A Comprehensive Review, Part II.

South Med J. 114: 614-619Delaunay M. Cadranel J. Lusque A. et al.

Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients.

Eur Respir J. 50: 1700050Khunger M. Rakshit S. Pasupuleti V. et al.

Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.

Chest. 152: 271-281Chuzi S. Tavora F. Cruz M. et al.

Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis.

Cancer Manag Res. 9: 207-213Wang H. Guo X. Zhou J. et al.

Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis.

Thorac Cancer. 11: 191-197Shi L. Tang J. Tong L. et al.

Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials.

Lung Cancer. 83: 231-239Yoneda K.Y. Scranton J.R. Cadogan M.A. et al.

Interstitial Lung Disease Associated With Crizotinib in Patients With Advanced Non-Small Cell Lung Cancer: Independent Review of Four PROFILE Trials.

Clin Lung Cancer. 18: 472-479Bergeron A. Réa D. Levy V. et al.

Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series.

Am J Respir Crit Care Med. 176: 814-818Ma Z. Sun X. Zhao Z. et al.

Risk of pneumonitis in cancer patients treated with PARP inhibitors: A meta-analysis of randomized controlled trials and a pharmacovigilance study of the FAERS database.

Gynecol Oncol. 162: 496-505Willemsen A.E.C.A.B. Grutters J.C. Gerritsen W.R. et al.

mTOR inhibitor-induced interstitial lung disease in cancer patients: Comprehensive review and a practical management algorithm.

Int J Cancer. 138: 2312-2321Sakamoto S. Kikuchi N. Ichikawa A. et al.

Everolimus-induced pneumonitis after drug-eluting stent implantation: a case report.

Cardiovasc Intervent Radiol. 36: 1151-1154

Everolimus-Eluting Stent-induced Pneumonitis.

Am J Respir Crit Care Med. 205: 12-13Cortés J. Kim S.-B. Chung W.-P. et al.

Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.

N Engl J Med. 386: 1143-1154Verma S. Miles D. Gianni L. et al.

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer.

N Engl J Med. 367: 1783-1791Tarantino P. Modi S. Tolaney S.M. et al.

Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates: A Review.

JAMA Oncol. 7: 1873-1881Abuhelwa Z. Alloghbi A. Alqahtani A. et al.

Trastuzumab Deruxtecan-Induced Interstitial Lung Disease/Pneumonitis in ERBB2-Positive Advanced Solid Malignancies: A Systematic Review.

Drugs. 82: 979-987Kremer J.M. Alarcón G.S. Weinblatt M.E. et al.

Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review.

Arthritis Rheum. 40: 1829-1837Imokawa S. Colby T.V. Leslie K.O. et al.

Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients.

Eur Respir J. 15: 373Le Guillou F. Dominique S. Dubruille V. et al.

[Acute respiratory distress syndrome due to pneumonitis following intrathecal methotrexate administration].

Rev Mal Respir. 20 (): 273-277Conway R. Low C. Coughlan R.J. et al.

Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trials.

Br Med J. 13: h1269

Dawson JK, Quah E, Earnshaw B, et al. Does methotrexate cause progressive fibrotic interstitial lung disease? A systematic review, Rheumatol Int, 41(6), 2021, 1055-1064.

Juge PA, Lee JS, Lau J, et al. Methotrexate and rheumatoid arthritis associated interstitial lung disease, Eur Respir J, 57(2), 2000337, 2021.

Perez-Alvarez R. Perez-de-Lis M. Diaz-Lagares C. et al.

Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases.

Semin Arthritis Rheum. 41: 256-264Theunssens X. Bricman L. Dierckx S. et al.

Anti-TNF Induced Sarcoidosis-Like Disease in Rheumatoid Arthritis Patients: Review Cases from the RA UCLouvain Brussels Cohort.

Rheumatol Ther. 9: 763-770

Pulmonary reactions to nitrofurantoin. 447 cases reported to the Swedish Adverse Drug Reaction Committee 1966-1976.

Eur J Respir Dis. 62: 180-189Sovijärvi A.R. Lemola M. Stenius B. et al.

Nitrofurantoin-induced acute, subacute and chronic pulmonary reactions.

Scand J Respir Dis. 58: 41-50Speirs T.P. Tuffin N. Mundy-Baird F. et al.

Long-term nitrofurantoin: an analysis of complication awareness, monitoring, and pulmonary injury cases.

BJGP Open. 5Hanania A.N. Mainwaring W. Ghebre Y.T. et al.

Radiation-Induced Lung Injury: Assessment and Management.

Chest. 156: 150-162Davis S.D. Yankelevitz D.F. Henschke C.I.

Radiation effects on the lung: clinical features, pathology, and imaging findings.

AJR Am J Roentgenol. 159: 1157-1164Schneider B.J. Naidoo J. Santomasso B.D. et al.

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.

J Clin Oncol. 39: 4073-4126Extracorporal Membrane Oxygenation (ECMO). () ()

Recurrent Pulmonary Infiltration and Pleural Effusion Due to Nitrofurantoin Sensitivity.

N Engl J Med. 266: 1024-1026